*case is detailed in the result section. alisted treatments are systemic treatments unless otherwise specified. btumor-free high-risk stage III melanoma (AJCC 2009); adjuvant administration of ipilimu
T-cell engagers (TCEs) are transformative immunotherapies with significant potential in treating hematologic malignancies and solid tumors. However, their real-world safety profiles remain inadequatel
We report results of transcriptional profiling of ex vivo MC38 murine organotypic tumor spheroids following programmed death-1 (PD-1) blockade compared to isotype control IgG treatment by bulk and sin
